Personalis Inc
PSNL5.535USD
+0.145+2.69%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
488.85MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Personalis Inc Unternehmen
Personalis, Inc. is engaged in developing and marketing advanced cancer genomic tests and analytics. The Company’s advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other next generation cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. The Company performed WGS on human samples for research projects, such as population sequencing initiatives. The Company’s tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, the development of personalized cancer therapies.
Unternehmensinformationen
BörsenkürzelPSNL
Name des UnternehmensPersonalis Inc
IPO-datumJun 20, 2019
CEOMr. Christopher M. (Chris) Hall
Anzahl der mitarbeiter229
WertpapierartOrdinary Share
GeschäftsjahresendeJun 20
Addresse6600 Dumbarton Circle
StadtFREMONT
BörseNASDAQ Global Market Consolidated
LandUnited States of America
Postleitzahl94555
Telefon16507521300
Websitehttps://www.personalis.com/
BörsenkürzelPSNL
IPO-datumJun 20, 2019
CEOMr. Christopher M. (Chris) Hall
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Aaron Tachibana
Mr. Aaron Tachibana
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
163.21K
-0.39%
Dr. Richard Chen, M.D.
Dr. Richard Chen, M.D.
Executive Vice President - Research and Development, Chief Medical Officer
Executive Vice President - Research and Development, Chief Medical Officer
120.75K
-0.37%
Ms. Lonnie Shoff
Ms. Lonnie Shoff
Independent Director
Independent Director
20.63K
+99.99%
Ms. Karin Eastham, CPA
Ms. Karin Eastham, CPA
Independent Chairman of the Board
Independent Chairman of the Board
13.51K
--
Mr. Stephen Moore
Mr. Stephen Moore
Senior Vice President, Chief Legal Officer, and Corporate Secretary
Senior Vice President, Chief Legal Officer, and Corporate Secretary
--
--
Mr. Woodrow A. (Woody) Myers, Jr., M.D.
Mr. Woodrow A. (Woody) Myers, Jr., M.D.
Independent Director
Independent Director
--
--
Ms. Olivia K. Bloom, CPA
Ms. Olivia K. Bloom, CPA
Independent Director
Independent Director
--
--
Mr. A. Blaine Bowman
Mr. A. Blaine Bowman
Independent Director
Independent Director
--
--
Mr. Christopher M. (Chris) Hall
Mr. Christopher M. (Chris) Hall
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Dr. Kenneth Jon (Ken) Widder, M.D.
Dr. Kenneth Jon (Ken) Widder, M.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Aaron Tachibana
Mr. Aaron Tachibana
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
163.21K
-0.39%
Dr. Richard Chen, M.D.
Dr. Richard Chen, M.D.
Executive Vice President - Research and Development, Chief Medical Officer
Executive Vice President - Research and Development, Chief Medical Officer
120.75K
-0.37%
Ms. Lonnie Shoff
Ms. Lonnie Shoff
Independent Director
Independent Director
20.63K
+99.99%
Ms. Karin Eastham, CPA
Ms. Karin Eastham, CPA
Independent Chairman of the Board
Independent Chairman of the Board
13.51K
--
Mr. Stephen Moore
Mr. Stephen Moore
Senior Vice President, Chief Legal Officer, and Corporate Secretary
Senior Vice President, Chief Legal Officer, and Corporate Secretary
--
--
Mr. Woodrow A. (Woody) Myers, Jr., M.D.
Mr. Woodrow A. (Woody) Myers, Jr., M.D.
Independent Director
Independent Director
--
--
Umsatzaufteilung
Währung: USDAktualisiert: Sun, Jul 6
Währung: USDAktualisiert: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Keine Daten
Nach RegionUSD
Name
Umsatz
Anteil
United States
18.13M
88.00%
Others
2.47M
12.00%
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Sat, Jul 26
Aktualisiert: Sat, Jul 26
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Merck & Co Inc
15.90%
Tempus AI Inc
14.40%
Lightspeed Venture Partners
9.24%
ARK Investment Management LLC
8.05%
AIGH Capital Management, LLC.
3.15%
Other
49.26%
Aktionäre
Aktionäre
Anteil
Merck & Co Inc
15.90%
Tempus AI Inc
14.40%
Lightspeed Venture Partners
9.24%
ARK Investment Management LLC
8.05%
AIGH Capital Management, LLC.
3.15%
Other
49.26%
Aktionärstypen
Aktionäre
Anteil
Corporation
30.30%
Investment Advisor
17.42%
Investment Advisor/Hedge Fund
10.89%
Venture Capital
9.33%
Hedge Fund
3.49%
Private Equity
3.15%
Research Firm
1.79%
Individual Investor
1.18%
Pension Fund
0.67%
Other
21.77%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
223
69.16M
78.30%
+787.53K
2025Q1
223
76.78M
86.93%
+10.49M
2024Q4
213
73.54M
83.34%
+21.51M
2024Q3
203
51.51M
73.15%
+1.63M
2024Q2
208
30.80M
57.54%
-8.76M
2024Q1
264
31.11M
59.99%
-9.40M
2023Q4
271
31.05M
62.33%
-8.25M
2023Q3
297
34.10M
70.92%
-7.87M
2023Q2
312
35.53M
73.99%
-8.07M
2023Q1
327
36.62M
78.29%
-6.81M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Merck & Co Inc
14.04M
15.9%
--
--
Mar 31, 2025
Tempus AI Inc
12.72M
14.4%
+3.50M
+37.97%
Aug 16, 2024
Lightspeed Venture Partners
8.16M
9.24%
--
--
Mar 31, 2025
ARK Investment Management LLC
7.19M
8.14%
+412.76K
+6.09%
Mar 31, 2025
AIGH Capital Management, LLC.
2.98M
3.37%
+176.67K
+6.30%
Mar 31, 2025
abrdn Inc.
1.70M
1.93%
+1.41M
+472.29%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.70M
1.92%
+6.34K
+0.37%
Mar 31, 2025
The Vanguard Group, Inc.
1.29M
1.46%
-444.30K
-25.61%
Mar 31, 2025
Blue Water Life Science Advisors, LP.
1.18M
1.33%
+42.50K
+3.75%
Mar 31, 2025
BlackRock Financial Management, Inc.
1.08M
1.22%
-20.66K
-1.87%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
ARK Genomic Revolution ETF
4.48%
Invesco NASDAQ Future Gen 200 ETF
0.64%
Global X Genomics & Biotechnology ETF
0.52%
iShares Micro-Cap ETF
0.07%
ProShares Ultra Nasdaq Biotechnology
0.06%
Invesco Nasdaq Biotechnology ETF
0.06%
iShares Biotechnology ETF
0.04%
Avantis US Small Cap Equity ETF
0.03%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.03%
iShares Russell 2000 Value ETF
0.02%
Mehr Anzeigen
ARK Genomic Revolution ETF
Anteil4.48%
Invesco NASDAQ Future Gen 200 ETF
Anteil0.64%
Global X Genomics & Biotechnology ETF
Anteil0.52%
iShares Micro-Cap ETF
Anteil0.07%
ProShares Ultra Nasdaq Biotechnology
Anteil0.06%
Invesco Nasdaq Biotechnology ETF
Anteil0.06%
iShares Biotechnology ETF
Anteil0.04%
Avantis US Small Cap Equity ETF
Anteil0.03%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Anteil0.03%
iShares Russell 2000 Value ETF
Anteil0.02%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
